These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 38603646)

  • 1. Mitoxantrone Versus Liposomal Daunorubicin in Induction of Pediatric AML With Risk Stratification Based on Flow Cytometry Measurement of Residual Disease.
    Tierens A; Arad-Cohen N; Cheuk D; De Moerloose B; Fernandez Navarro JM; Hasle H; Jahnukainen K; Juul-Dam KL; Kaspers G; Kovalova Z; Lausen B; Norén-Nyström U; Palle J; Pasauliene R; Jan Pronk C; Saks K; Zeller B; Abrahamsson J
    J Clin Oncol; 2024 Jun; 42(18):2174-2185. PubMed ID: 38603646
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Measurable Residual Disease at Induction Redefines Partial Response in Acute Myeloid Leukemia and Stratifies Outcomes in Patients at Standard Risk Without NPM1 Mutations.
    Freeman SD; Hills RK; Virgo P; Khan N; Couzens S; Dillon R; Gilkes A; Upton L; Nielsen OJ; Cavenagh JD; Jones G; Khwaja A; Cahalin P; Thomas I; Grimwade D; Burnett AK; Russell NH
    J Clin Oncol; 2018 May; 36(15):1486-1497. PubMed ID: 29601212
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial.
    Rubnitz JE; Inaba H; Dahl G; Ribeiro RC; Bowman WP; Taub J; Pounds S; Razzouk BI; Lacayo NJ; Cao X; Meshinchi S; Degar B; Airewele G; Raimondi SC; Onciu M; Coustan-Smith E; Downing JR; Leung W; Pui CH; Campana D
    Lancet Oncol; 2010 Jun; 11(6):543-52. PubMed ID: 20451454
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improved outcome in pediatric relapsed acute myeloid leukemia: results of a randomized trial on liposomal daunorubicin by the International BFM Study Group.
    Kaspers GJ; Zimmermann M; Reinhardt D; Gibson BE; Tamminga RY; Aleinikova O; Armendariz H; Dworzak M; Ha SY; Hasle H; Hovi L; Maschan A; Bertrand Y; Leverger GG; Razzouk BI; Rizzari C; Smisek P; Smith O; Stark B; Creutzig U
    J Clin Oncol; 2013 Feb; 31(5):599-607. PubMed ID: 23319696
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of the detection of minimal residual disease for the prognosis and the choice of post-remission therapy of intermediate-risk acute myeloid leukemia without FLT3-ITD, NPM1 and biallelic CEBPA mutations.
    Zheng WS; Hu YL; Guan LX; Peng B; Wang SY
    Hematology; 2021 Dec; 26(1):179-185. PubMed ID: 33594943
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improved outcomes for myeloid leukemia of Down syndrome: a report from the Children's Oncology Group AAML0431 trial.
    Taub JW; Berman JN; Hitzler JK; Sorrell AD; Lacayo NJ; Mast K; Head D; Raimondi S; Hirsch B; Ge Y; Gerbing RB; Wang YC; Alonzo TA; Campana D; Coustan-Smith E; Mathew P; Gamis AS
    Blood; 2017 Jun; 129(25):3304-3313. PubMed ID: 28389462
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Defining the Optimal Total Number of Chemotherapy Courses in Younger Patients With Acute Myeloid Leukemia: A Comparison of Three Versus Four Courses.
    Burnett AK; Russell NH; Hills RK; Knapper S; Freeman S; Huntly B; Clark RE; Thomas IF; Kjeldsen L; McMullin MF; Drummond M; Kell J; Spearing R
    J Clin Oncol; 2021 Mar; 39(8):890-901. PubMed ID: 33356418
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FLT3-ITD Allelic Ratio and NPM1 Mutation Do Not Impact Outcomes in Acute Myeloid Leukemia Patients with FLT3-ITD after Allogeneic Hematopoietic Stem Cell Transplantation: A Retrospective Propensity Score- Matching Study.
    Zhou C; Zheng F; Xu L; Zhang X; Chang Y; Mo X; Sun Y; Huang X; Wang Y
    Transplant Cell Ther; 2023 Jul; 29(7):456.e1-456.e11. PubMed ID: 37028555
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Allogeneic hematopoietic stem cell transplantation can improve the prognosis of high-risk pediatric t(8;21) acute myeloid leukemia in first remission based on MRD-guided treatment.
    Hu GH; Cheng YF; Lu AD; Wang Y; Zuo YX; Yan CH; Wu J; Sun YQ; Suo P; Chen YH; Chen H; Jia YP; Liu KY; Han W; Xu LP; Zhang LP; Huang XJ
    BMC Cancer; 2020 Jun; 20(1):553. PubMed ID: 32539815
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Liposomal daunorubicin versus standard daunorubicin: long term follow-up of the GIMEMA GSI 103 AMLE randomized trial in patients older than 60 years with acute myelogenous leukaemia.
    Latagliata R; Breccia M; Fazi P; Iacobelli S; Martinelli G; Di Raimondo F; Sborgia M; Fabbiano F; Pirrotta MT; Zaccaria A; Amadori S; Caramatti C; Falzetti F; Candoni A; Mattei D; Morselli M; Alimena G; Vignetti M; Baccarani M; Mandelli F
    Br J Haematol; 2008 Dec; 143(5):681-9. PubMed ID: 18950458
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Minimal residual disease detected by multiparameter flow cytometry is complementary to genetics for risk stratification treatment in acute myeloid leukemia with biallelic CEBPA mutations.
    Deng DX; Zhu HH; Liu YR; Chang YJ; Ruan GR; Jia JS; Jiang H; Jiang Q; Zhao XS; Huang XJ
    Leuk Lymphoma; 2019 Sep; 60(9):2181-2189. PubMed ID: 30773106
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of pre-transplantation minimal residual disease determined by multiparameter flow cytometry on the outcome of AML patients with FLT3-ITD after allogeneic stem cell transplantation.
    Zhao X; Wang Z; Ruan G; Liu Y; Wang Y; Zhang X; Xu L; Huang X; Chang Y
    Ann Hematol; 2018 Jun; 97(6):967-975. PubMed ID: 29423758
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Decreased relapsed rate and treatment-related mortality contribute to improved outcomes for pediatric acute myeloid leukemia in successive clinical trials.
    Alexander TB; Wang L; Inaba H; Triplett BM; Pounds S; Ribeiro RC; Pui CH; Rubnitz JE
    Cancer; 2017 Oct; 123(19):3791-3798. PubMed ID: 28556917
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improved treatment results in high-risk pediatric acute myeloid leukemia patients after intensification with high-dose cytarabine and mitoxantrone: results of Study Acute Myeloid Leukemia-Berlin-Frankfurt-Münster 93.
    Creutzig U; Ritter J; Zimmermann M; Reinhardt D; Hermann J; Berthold F; Henze G; Jürgens H; Kabisch H; Havers W; Reiter A; Kluba U; Niggli F; Gadner H
    J Clin Oncol; 2001 May; 19(10):2705-13. PubMed ID: 11352963
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of induction chemotherapy with intermediate-dosed cytarabine and subsequent allogeneic stem cell transplantation on the outcome of high-risk acute myeloid leukemia.
    Fleischmann M; Schnetzke U; Frietsch JJ; Sayer HG; Schrenk K; Hammersen J; Glaser A; Hilgendorf I; Hochhaus A; Scholl S
    J Cancer Res Clin Oncol; 2022 Jun; 148(6):1481-1492. PubMed ID: 34297206
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of Persistent Minimal Residual Disease with Poor Outcomes of Patients with Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Stem Cell Transplantation.
    Liu J; Zhao XS; Liu YR; Xu LP; Zhang XH; Chen H; Chen YH; Wang FR; Han W; Sun YQ; Yan CH; Tang FF; Mo XD; Liu KY; Fan QZ; Huang XJ; Chang YJ
    Chin Med J (Engl); 2018 Dec; 131(23):2808-2816. PubMed ID: 30511683
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Wilms' tumor gene 1 is an independent prognostic factor for pediatric acute myeloid leukemia following allogeneic hematopoietic stem cell transplantation.
    Deng DX; Wen JJ; Cheng YF; Zhang XH; Xu LP; Wang Y; Yan CH; Chen YH; Chen H; Han W; Wang FR; Wang JZ; Qin YZ; Liu KY; Huang XJ; Zhao XS; Mo XD
    BMC Cancer; 2021 Mar; 21(1):292. PubMed ID: 33740924
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Improved treatment results in children with AML: Results of study AML-BFM 93].
    Creutzig U; Berthold F; Boos J; Fleischhack G; Gadner H; Gnekow A; Graubner U; Henze G; Hermann J; Imbach P; Jürgens H; Kabisch H; Körholz D; Niemeyer CM; Reinhardt D; Reiter A; Ritter J; Spaar HJ; Zimmermann M;
    Klin Padiatr; 2001; 213(4):175-85. PubMed ID: 11528551
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interferon-α Is Effective for Treatment of Minimal Residual Disease in Patients with t(8;21) Acute Myeloid Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation: Results of a Prospective Registry Study.
    Mo XD; Wang Y; Zhang XH; Xu LP; Yan CH; Chen H; Chen YH; Qin YZ; Liu KY; Huang XJ
    Oncologist; 2018 Nov; 23(11):1349-1357. PubMed ID: 30076280
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Analysis of 7 cases of pediatric acute myeloid leukemia with DEK-NUP214 fusion gene].
    Li XL; Liu LP; Wan Y; Liu F; Chen X; Ren YY; Ruan M; Guo Y; Zhu XF; Yang WY
    Zhonghua Er Ke Za Zhi; 2023 Apr; 61(4):357-362. PubMed ID: 37011983
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.